Evidence map›Paper›PMID 40820260›Full record

ArticleMacromolecular bioscience2025

Hydrophobic Drug Delivery into T Cells Using Carboxy-Terminal Phenylalanine-Modified Dendrigraft Polylysines.

Chie Kojima, Akinobu Sakai, Tetsuya Kadonosono

Abstract read
In one paragraph

Article in Macromolecular bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Chie KojimaDepartment of Materials Science and Engineering, School of Materials and Chemical Technology, Institute of Science Tokyo, Yokohama, Kanagawa, Japan.ORCID 0000-0002-2208-5784
Akinobu SakaiDepartment of Materials Science and Engineering, School of Materials and Chemical Technology, Institute of Science Tokyo, Yokohama, Kanagawa, Japan.
Tetsuya KadonosonoDepartment of Life Science and Technology, School of Life Science and Technology, Institute of Science Tokyo, Yokohama, Kanagawa, Japan.

Funding

JSPS KAKENHI JP 22H04556SEKISUI CHEMICAL CO 612
6 · The paper itself

Abstract

T cells in the lymph nodes play an important role in cancer immunotherapy. Dendrigraft polylysines (DGLs) are potent nanoplatforms used in nanomedicine. In the present study, DGLs were modified with 1,2-cyclohexanedicarboxylic acid (CHex) and phenylalanine (Phe) to produce DGL-CHex-Phe for drug delivery into T cells. Various DGL-CHex-Phe polymers were synthesized using different generations of DGL by reacting with Phe at different ratios. DGL-CHex-Phe polymers with a higher generation and more Phe efficiently associated with Jurkat cells, a T cell model. These polymers are internalized by T cells via an amino acid transporter and/or direct membrane association. The hydrophobic model drug, paclitaxel (PTX), was loaded onto the polymers. DGL(G3)-CHex-Phe93 loaded the most PTX molecules among them, and most of them were retained therein for 3 h. PTX-loaded polymers exhibited cytotoxic effects against Jurkat cells at a level similar to that of free PTX. DGL(G3)-CHex-Phe93 efficiently accumulated in lymph nodes after intradermal injection, which was partially co-localized with T cells. These results suggested that DGL(G3)-CHex-Phe93 is useful for the delivery of hydrophobic drugs into immune cells including T cells in lymph nodes.

Indexed as

DendrimersDrug Delivery SystemsPaclitaxelPhenylalaninePolylysineT-LymphocytesAnimalsHumansHydrophobic and Hydrophilic InteractionsJurkat CellsDendrimersPaclitaxelPhenylalaninePolylysinedendritic polymerlymph nodephenylalaninepolylysineT cells

Identifiers

PMID40820260
PMCPMC12617687

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.